|
ORF cDNA clones
|
CRISPR / TALEN
|
Lentivirus
|
AAV
|
TALE-TF
|
ORF knockin clones
|
|
Antibody
|
Proteins
|
miRNA target clones
|
qPCR primers
|
shRNA clones
|
miRNA products
|
Promoter clones
|
Validated All-in-One™ qPCR Primer for CTAG1B(NM_001327.2) Search again
Product ID:
HQP003453
(click here to view gene annotation page)
Powered by BiozSpecies:
Human
Symbol:
Alias:
CT6.1, CTAG, CTAG1, ESO1, LAGE-2, LAGE2B, NY-ESO-1
Gene Description:
cancer/testis antigen 1B
Target Gene Accession:
NM_001327.2(click here to view gene page)
Estimated Delivery:
Approximately 1-3 weeks, but may vary. Please email sales@genecopoeia.com or call 301-762-0888 to confirm ETA.
Important Note:
By default, qPCR primer pairs are designed to measure the expression level of the splice variant (accession number) you selected for this gene WITHOUT consideration of other possible variants of this gene. If this gene has multiple variants, and you would like to measure the expression levels of one particular variant, multiple variants, or all variants, please contact us for a custom service project at inquiry@genecopoeia.com.
Validated result:
|
|
| A | B |
|
Each All-in-One™ qPCR Primer is experimentally validated to yield a single dissociation curve peak and to generate a single amplification of the correct size for the targeted gene. A cDNA Pool, containing reverse transcript products of 8 different human tissue total RNA(Liver, Testis,Muscle,Thyroid,Brain,Spleen,Stomach,Small Intestine)),was used as the qPCR validation template. qPCR was performed using 0.2 µM primer with 2XAll-in-One™ qPCR Mix (Catalog#: QP001,QP002,QP004,QP005). Reactions were incubated for 10min. at 95°C, followed by 40 cycles of 95°C for 10 sec.; 60°C, 20 sec. and 72°C, 15sec. using Bio-Rad iQ5™ Instrument. At the end of the last cycle, temperature was increased from 72 to 95°C to produce a melting curve. Panel A: Validated Result for Amplification Curve; Panel B: Validated Result for Melting Curve. |
|
Summary
Cancer/testis antigens, such as CTAG1B, are expressed in a variety of malignant tumors but soley in testis among normal adult tissues (Yoshida et al., 2006 [PubMed 16596224]).[supplied by OMIM].
Gene References into function
- NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells.
- NY-ESO-1 is a marker that can be used to follow the early progression of testicular tumorigenesiswhen the tumors express a similar pattern to the cells of origin,although later tumors cease to express NY-ESO-1.
- abilities of human monocyte-derived DCs and DCs derived in vitro from CD34-positive stem cells to present NY-ESO-1 epitopes to MHC class I-restricted cytotoxic T cells
- strong MAGE-A4 expression and to a lesser degree NY-ESO-1 expression is characteristic of the vast majority of uterine carcinosarcomas and a major subset of papillary serous carcinomas
- NY-ESO-1 gene is expressed highly in esophageal carcinoma
- naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses
- NY-ESO-1 mRNA expression, specific antibodies and CD8 T cell responses in advanced prostate cancer.
- NY-ESO-1 was highly expressed in dendritic cells with a bicistronic retroviral vector.
- Data showed aberrant expression of NY-ESO-1 and LAGE-1 by IHC/RT-PCR in a significant proportion of epithelial ovarian cancer patients.
- NY-ESO-1-specific CD4(+) and CD8(+) T cells were also able to recognize NY-ESO-1 expressing neuroblastoma cells.
- Higher rate of NY-ESO-1 expression was noted in breast cancer with high histological grade and negative hormone receptor status
- results demonstrate that the NY-ESO-1 expression was frequently present in primary NSCLC, especially advanced cases with lymph node metastasis
- NY-ESO-1 induces tumor-specific humoral and cellular immune responses in hepatocellular carcinoma
- Data show that recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans.
- The high expression frequency of NY-ESO-1 mRNA and protein indicates NY-ESO-1 as a feasible vaccine target in esophageal cancer.
- NY-ESO-1 spontaneously induces HLA-DP4-restricted CD4+ Th1 and Th2 responses in a significant proportion of patients with epithelial ovarian cancer.
- NY-ESO-1 is frequently expressed in multiple myeloma with cytogenetic abnormality
- Present, by immunocytochemistry, in normal prostate, prostatic hypertrophy and prostate cancer.
- Data indicate that reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter mediates epigenetic regulation of this CT gene in lung cancer cells.
- HLA-peptide presentation is directly visualized for the first time, demonstrating that NY-ESO-1/LAGE-1-positive tumor cells present 10-50 NY-ESO-1/LAGE-1(157-165) epitopes per cell.
- NY-ESO-1 directly engages the innate immune system through calreticulin present on dendritic cells, macrophages, and monocytes.
- found strong antibody responses against CT antigens preferentially in patients who had received allogeneic stem cell transplantation
- This is the first report of direct interaction between two CT antigens (MAGE-C1 and NY-ESO-1) and may be pertinent in the light of the frequently coordinated expression of these proteins
- MAGE-A1 and NY-ESO-1 are associated with highly proliferating germ cells, whereas GAGE proteins have a more general function in germ cells unrelated to any specific developmental stage
- usefulness of NY-ESO-1 as a tool for tumor vaccine therapy in eliciting NY-ESO-1-specific helper T-cell responses, especially in Japanese cancer patients.
- NY-ESO-1 is more frequently expressed in metastatic than in primary malignant melanoma and its expression is associated with thicker primary lesions and a higher frequency of metastatic disease, indicative of a worse prognosis.
- immunization with NY-ESO-1 peptides leads to strong tumor-reactive CD8+ T-cell responses
- NY-ESO-1 overexpression increases as the malignancy grade of the astrocytic tumors increases.
- Autoantibodies to NY-ESO-1 were associated with increased tumor-infiltrating CD8+, CD4+ and FoxP3+ cells in ovarian cancer patients
- Its expression is significantly associated with prognostic factors in poor outcome of the non-small cell lung cancer.